# Therapeutic Goods Administration (TGA) Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/therapeutic-goods-administration-tga Canonical HTML page: https://getyourbrief.com/entity/therapeutic-goods-administration-tga ## Timeline - **2026**: Implementation — New pricing structures and stricter clinical criteria for reimbursement are expected to take effect. - **2026-02-27**: TGA Approval — Australian regulators approve the Virtual Nodule Clinic for clinical use. - **2026-02-27**: Subsidy Cut Announcement — Government announces plans to slash subsidies for SCS devices based on findings that they 'don't work' for many patients. - **2025**: Regulatory Review — The TGA and Department of Health initiate a formal review into the clinical efficacy of spinal cord stimulators. - **2024-02-27**: Public Advocacy Surge — Increased media coverage and patient advocacy highlight the pricing disparity between genders. - **2024**: Rising Adverse Events — Increased reporting of 'failed back surgery syndrome' and device-related injuries in Australian hospitals. - **2022-09-20**: Series A Funding — Company raises $14M to scale global commercial operations. - **2021-03-15**: FDA Clearance — Optellum receives first-of-its-kind FDA clearance for lung cancer AI. - **2020-11-15**: TGA Approval — The Therapeutic Goods Administration approves the first female-specific testosterone cream. - **2019-09-01**: Global Consensus Statement — International medical societies reach consensus on testosterone use for women's sexual health. ## Recent coverage (8 stories, network-wide) ### Patient Advocacy Signals Growth in Medicinal Cannabis for PTSD Treatment 2026-03-20 23:02:59 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Bilal Cassim’s public testimony regarding the efficacy of medicinal cannabis for PTSD and sleep disorders highlights a growing trend of patient-led advocacy in Australia. This case underscores the shifting clinical landscape as researchers and regulators grapple with the integration of cannabinoid therapies into standard psychiatric care. Full story: https://getbiobrief.com/story/medicinal-cannabis-ptsd-patient-advocacy-australia ### Medicinal Cannabis Adoption Surges for PTSD and Sleep Disorders in Australia 2026-03-20 23:02:56 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The public endorsement of medicinal cannabis by patients like Bilal Cassim for PTSD and insomnia highlights a significant shift in Australian healthcare toward cannabinoid therapies. This trend reflects a broader move toward alternative mental health treatments as the clinical and regulatory landscape continues to evolve. Full story: https://gethealthbrief.com/story/medicinal-cannabis-ptsd-sleep-trends-australia ### Lancet Study Challenges Efficacy of Medicinal Cannabis for Mental Health 2026-03-17 00:59:26 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 A comprehensive study published in The Lancet concludes that medicinal cannabis is largely ineffective for treating anxiety, depression, and PTSD. These findings challenge the rapidly growing global market for cannabinoid-based mental health treatments and highlight a significant gap between patient perception and clinical evidence. Full story: https://getbiobrief.com/story/lancet-study-medicinal-cannabis-ineffective-mental-health ### Australia Slashes Subsidies for Spinal Implants Amid Safety Concerns 2026-02-27 09:19:25 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 3 The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies. Full story: https://getbiobrief.com/story/australia-spinal-implant-subsidy-cuts ### Australia Slashes Spinal Implant Subsidies Over Safety and Efficacy Concerns 2026-02-27 09:18:50 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 3 The Australian government is significantly reducing funding for expensive spinal cord stimulators following reports linking the devices to severe patient injuries. This regulatory shift follows a clinical review that found the high-cost implants often provide no long-term benefit over conservative care. Full story: https://gethealthbrief.com/story/australia-spinal-implant-subsidy-cuts ### Australian Regulators to Slash Subsidies for High-Risk Spinal Implants 2026-02-27 09:16:11 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 3 The Australian government is moving to drastically reduce subsidies for spinal cord stimulators following evidence of severe patient injuries and a lack of clinical efficacy. This regulatory pivot marks a major shift in medical device reimbursement, prioritizing long-term safety over industry-led innovation claims. Full story: https://getlegalbrief.com/story/australia-spinal-implant-subsidy-cuts-regulation ### Australia's Testosterone Gender Gap: Women Face Higher Costs for Vital Therapy 2026-02-27 02:58:12 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework. Full story: https://gethealthbrief.com/story/australia-testosterone-gender-gap-pricing ### Optellum Gains TGA Approval for AI Lung Cancer Diagnostic Tool in Australia 2026-02-27 02:29:49 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3 Optellum has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. This expansion allows Australian clinicians to utilize advanced imaging analytics to improve early lung cancer detection and streamline patient care pathways. Full story: https://gethealthbrief.com/story/optellum-tga-approval-australia-lung-cancer-ai --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.